TESARO, Inc.
5/25/2017

TESARO Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three ZEJULA™ (niraparib) abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to June 6, 2017, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 3 at 6:00 PM local time in conjunction with the ASCO Annual Meeting.

"We're excited to see presentations of additional data from the landmark ENGOT-OV16/NOVA trial presented at this year's ASCO Annual Meeting," said Mary Lynne Hedley, Ph.D., President and COO, TESARO. "We also look forward to sharing initial data from the TOPACIO trial of niraparib plus pembrolizumab, as well as data from the Phase 1 trial of TSR-042, our anti-PD-1 antibody, at our ASCO investor briefing."

Please plan to visit TESARO at Booth #18097 to learn more about ZEJULA™ (niraparib), VARUBI® (rolapitant) and our immuno-oncology pipeline.

Presentation Details:

Saturday, June 3, 2017, 1:15 PM to 4:45PM
Efficacy of Niraparib on Progression-free Survival (PFS) in Patients (Pts) with Recurrent Ovarian Cancer (OC) with Partial Response to the Last Platinum-based Chemotherapy
Abstract #5517, Poster Board #339, Location: Hall A
Poster Discussion: Saturday, June 3, 2017, 4:45 PM to 6:00 PM, Location: Aerie Crown Theater

Saturday, June 3, 2017, 1:15 PM to 4:45PM
Long-Term Benefit of Niraparib Treatment of Recurrent Ovarian Cancer (OC)
Abstract #5534, Poster Board #356, Location: Hall A

Saturday, June 3, 2017, 1:15 PM to 4:45PM
The Successful Phase 3 Niraparib ENGOT-OV16/NOVA Trial Included a Substantial Number of Patients with Platinum Resistant Ovarian Cancer
Abstract #5560, Poster Board #382, Location: Hall A

Investor Briefing and Webcast
TESARO will host an investor and analyst briefing in Chicago on Saturday, June 3 at 6:15 PM local time in conjunction with the ASCO Annual Meeting. A reception will begin at 6:00 PM CT, preceding the presentation. During this briefing, TESARO management will provide a business overview and pipeline update and will answer questions from investors and analysts. This event will be webcast live and archived for 30 days, and may be accessed from the TESARO Investor Events and Presentations webpage at www.tesarobio.com.

About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com and follow us on Twitter and LinkedIn.

Investor/Media Contact:
Jennifer Davis
Vice President, Corporate Affairs & Investor Relations
+1.781.325.1116 or jdavis@tesarobio.com